In terms of safety, while no significant differences in the overall rates of adverse events were detected among the four treatment regimens examined in this study, continued vigilance is necessary for the potential elevation of transaminases (particularly alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), thrombocytosis, and hyperbilirubinemia during hetrombopag treatment for CIT (20). Here, GPT is linked to thrombocytosis disease.